Key Takeaways
- dsm-firmenich agreed to divest its Animal Nutrition & Health (ANH) business to CVC.
- The transaction values ANH at approximately €2.2 billion, including a potential earnout.
- dsm-firmenich will retain a 20% equity stake in the divested businesses.
- The divestment marks dsm-firmenich’s final step toward becoming a pure consumer-focused company.
- Completion of the transaction is expected by the end of 2026, subject to regulatory approvals.
dsm-firmenich Announces Divestment of Animal Nutrition & Health Unit
dsm-firmenich announced that it has entered into an agreement with CVC, a global private markets manager, to divest its Animal Nutrition & Health (ANH) business for an enterprise value of approximately €2.2 billion, including an earnout of up to €0.5 billion. As part of the transaction, dsm-firmenich will retain a 20% equity stake in the divested ANH companies alongside CVC.
The divestment follows the 2025 sale of dsm-firmenich’s Feed Enzymes activities to Novonesis for €1.5 billion and represents the final strategic step in dsm-firmenich’s transition to a fully focused consumer company operating in nutrition, health, and beauty. Including the prior Feed Enzymes transaction, the total enterprise value of the ANH divestment amounts to €3.7 billion.
“Today marks the final step in that journey,” said Dimitri de Vreeze, Chief Executive Officer of dsm-firmenich. “This transaction reflects our commitment to accelerating growth and creating long-term value for all stakeholders.”
4 Comments